Response Biomedical Poster Wins American Association for Clinical Chemistry Award



    VANCOUVER, June 25 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) today announced that its poster, Clinical Concordance for
Exclusion of Acute Heart Failure Using the RAMP(R) and Dade Dimension RxL
NT-proBNP Assays, poster number A-29, has been chosen as the winner of the
Critical and Point-of-Care Testing Abstract Award for Outstanding Research in
Critical Care and Point-of-Care Testing. The award will be presented at the
Critical and Point-of-Care Testing (CPOCT) Division Meeting in San Diego next
month. CPOCT is a division of the American Association of Clinical Chemistry
(AACC).
    "This abstract demonstrates that our RAMP NT-proBNP assay, with results
available in 15 minutes, shows excellent clinical agreement with the Dade
Dimension RxL, a market leading centralized laboratory system," said Bill
Radvak, President and CEO. "The National Association for Clinical Biochemistry
has recommended a turnaround time of not greater than 60 minutes for
natriuretic peptide assays to improve patient care. As it can often take
longer than 1 hour for centralized laboratory systems to provide results back
to the physician, the combined speed and accuracy of the RAMP NT-proBNP assay
can be an important new tool to provide near real time results leading to
better outcomes for the patient with compromised heart function. Further, a
recent 500 patient Canadian study reported in Circulation, which is published
by the American Heart Association, reported that knowledge of NT-proBNP
results reduced the duration of the emergency department visit, the number of
patients re-hospitalized, and direct medical costs of all emergency department
visits, hospitalizations and subsequent outpatient services. In fact, the use
of NT-proBNP tests in this study reduced total direct medical costs to the
healthcare system by 15%. (Circulation. 2007; 115,2103-3110.)
    The RAMP poster showcases data from a clinical trial conducted at the
Laboratoire de Biochimie Générale et Spécialsée, Hôpital Civil, Strasbourg,
France. The aim of the study was to compare the RAMP point-of-care (POC) and
laboratory based Dade Dimension RxL systems for measurement of NT-proBNP
levels in patients suspected of having heart failure (HF). Clinical
concordance analysis showed excellent clinical agreement between the RAMP and
the Dimension RxL. The RAMP NT-proBNP whole blood assay was shown to be an
accurate indicator that can be used to rule out acute HF in the trial's
patient population, with results comparable to the Dimension RxL laboratory
analyzer. With results available in 15 minutes, the RAMP NT-proBNP Assay
allows for rapid initiation of appropriate patient treatment.
    "We are very pleased that our poster is being recognized for outstanding
research. AACC provides leadership in advancing the practice and profession of
clinical laboratory science and its application to health care and we are
honored to be singled out by such a prestigious group," continued Bill Radvak.
    Response Biomedical has a RAMP NT-proBNP Test for the diagnosis of
congestive heart failure (CHF). The test has completed clinical trials and has
been submitted to the U.S. Food and Drug Administration, under a 510(k)
application, for clearance to commercialize the product in the U.S. The
product currently is available commercially in Europe and has just recently
been licensed in Canada.

    About Response Biomedical

    Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and laboratory use. The RAMP system
consists of a portable fluorescent reader and single-use disposable test
cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP clinical tests are
commercially available for the early detection of heart attack and congestive
heart failure.
    In late 2006, the Company formed a strategic alliance with 3M Company to
commercialize rapid infectious disease tests. In the non-clinical market, RAMP
Tests are currently provided for the environmental detection of West Nile
Virus, and Biodefense applications including the rapid on-site detection of
anthrax, smallpox, ricin and botulinum toxin. Several other product
applications are under development. The Company has achieved CE Marking and
its Quality Management System is registered to ISO 13485: 2003 and ISO 9001:
2000.
    Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at www.responsebio.com.

    Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
    Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, technological changes
that impact our existing products or our ability to develop and commercialize
our products; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; our ability
to obtain and maintain rights to technology from licensors; liability for
patent, product liability and other claims asserted against us;
commercialization limitations imposed by patents owned or controlled by third
parties; technical risk in research and development; adverse results or
unexpected delays in product development and clinical trials; our ability to
effectively and efficiently manage the planned growth of our operations; our
ability to obtain, and the timing of, necessary regulatory approvals;
competition including competition from others with significantly more
resources; market acceptance of our products and the size of our markets;
changes in business strategy or development plans; general economic and
business conditions where we operate; and other factors referenced in our
annual report on Form 20-F and other filings with Canadian and United States
securities regulatory authorities.
    Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments.





For further information:

For further information: Response Biomedical Contacts: Bill Wickson,
Manager, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email: bwickson@responsebio.com; Brian Korb, Vice President, The
Trout Group LLC, Tel: (646) 378-2923, Email: bkorb@troutgroup.com

Organization Profile

RESPONSE BIOMEDICAL CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890